Wecome Pharmaceutical Co Ltd (300878) - Total Assets
Based on the latest financial reports, Wecome Pharmaceutical Co Ltd (300878) holds total assets worth CN¥1.49 Billion CNY (≈ $217.74 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Wecome Pharmaceutical Co Ltd for net asset value and shareholders' equity analysis.
Wecome Pharmaceutical Co Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Wecome Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.
Wecome Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Wecome Pharmaceutical Co Ltd's total assets of CN¥1.49 Billion consist of 37.3% current assets and 62.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 15.4% |
| Accounts Receivable | CN¥217.87 Million | 13.2% |
| Inventory | CN¥118.32 Million | 7.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥33.59 Million | 2.0% |
| Goodwill | CN¥10.97 Million | 0.7% |
Asset Composition Trend (2013–2024)
This chart illustrates how Wecome Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Wecome Pharmaceutical Co Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Wecome Pharmaceutical Co Ltd's current assets represent 37.3% of total assets in 2024, a decrease from 61.5% in 2013.
- Cash Position: Cash and equivalents constituted 15.4% of total assets in 2024, down from 28.5% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, unchanged from 2.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 13.2% of total assets.
Wecome Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Wecome Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Wecome Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.34 | 5.16 | 4.67 |
| Quick Ratio | 1.97 | 4.45 | 4.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥305.01 Million | CN¥635.79 Million | CN¥784.97 Million |
Wecome Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Wecome Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.05 |
| Latest Market Cap to Assets Ratio | 0.37 |
| Asset Growth Rate (YoY) | -19.3% |
| Total Assets | CN¥1.65 Billion |
| Market Capitalization | $605.54 Million USD |
Valuation Analysis
Below Book Valuation: The market values Wecome Pharmaceutical Co Ltd's assets below their book value (0.37x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Wecome Pharmaceutical Co Ltd's assets decreased by 19.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Wecome Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual total assets of Wecome Pharmaceutical Co Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.65 Billion ≈ $241.79 Million |
-19.27% |
| 2023-12-31 | CN¥2.05 Billion ≈ $299.49 Million |
+6.94% |
| 2022-12-31 | CN¥1.91 Billion ≈ $280.05 Million |
+13.02% |
| 2021-12-31 | CN¥1.69 Billion ≈ $247.78 Million |
+3.96% |
| 2020-12-31 | CN¥1.63 Billion ≈ $238.34 Million |
+85.96% |
| 2019-12-31 | CN¥875.87 Million ≈ $128.17 Million |
+36.62% |
| 2018-12-31 | CN¥641.12 Million ≈ $93.82 Million |
+33.64% |
| 2017-12-31 | CN¥479.74 Million ≈ $70.20 Million |
+52.23% |
| 2016-12-31 | CN¥315.14 Million ≈ $46.12 Million |
+42.03% |
| 2015-12-31 | CN¥221.89 Million ≈ $32.47 Million |
+28.23% |
| 2014-12-31 | CN¥173.04 Million ≈ $25.32 Million |
+61.53% |
| 2013-12-31 | CN¥107.13 Million ≈ $15.68 Million |
-- |
About Wecome Pharmaceutical Co Ltd
Zhejiang Wecome Pharmaceutical Company Limited engages in the research and development, production, and sale of modern traditional Chinese and western medicine in China. The company offers products in various forms, including hard capsules, tablets, granules, soft capsules, pills, and other dosage forms. It also operates the retail of pharmaceutical commercial products. The company was formerly k… Read more